Safety observations
How much reassurance does the record offer?
I respect a selective hormone response. I’m much harder to satisfy about safety over time.
The perioperative observation window
In the randomized bowel-resection trial, treatment-emergent adverse events were reported in 87.5% of the ipamorelin arm and 94.8% of the placebo arm. The study reported no ipamorelin-specific safety signal in that short perioperative window.
I distrust reassurance drawn simply from the lower percentage in the treatment arm. These were adults undergoing bowel resection, observed around surgery. The result describes that setting. A claim about longer use in another population needs observations covering that use and population.
The small healthy-volunteer study adds acute intravenous exposure and hormone-response information in healthy men. Put beside the surgical trial, it makes the narrowness of the human record quite visible. Those are valuable experiments, and I still cannot extract a settled long-term safety verdict from them.
The longer-term question
A gerontology review identifies ipamorelin among non-approved peptides lacking long-term safety data and systematic validation. Another review of peptide safety and athletic performance emphasizes the scarcity of rigorous human safety data and the potential for serious harm.
My threshold for reassurance would require ipamorelin-specific human follow-up long enough to address sustained exposure, with meaningful clinical outcomes and careful adverse-event assessment.
The original selectivity work remains impressive within its acute animal setting. It contributes one kind of information to the safety question. The short human record and the class-level warning contribute others. Together they leave the longer-term ipamorelin question unresolved.